Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COBRA - Chemoablation for Low Grade Bladder Cancer: A Single Arm, Prospective, Open-label, Investigator-initiated Phase 2 Study

NCT07019220 is registered in ClinicalTrials.gov with Ekaterina Laukhtina as lead sponsor.

NCT NCT07019220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07019220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COBRA - Chemoablation for Low Grade Bladder Cancer: A Single Arm, Prospective, Open-label, Investigator-initiated Phase 2 Study
Lead sponsor
Ekaterina Laukhtina
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2023
Completion date
November 30, 2027
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer